Cancer Focus — Full Portfolio
3 tracked investments · listed companies and verified rows first
NectinTxnectintx.com✓ verified
Nectin Therapeutics develops novel monoclonal antibodies and antibody-drug-conjugates to treat difficult-to-treat cancers by targeting immune evasion mechanisms.
BiotechDeep TechMedical Devices
Co-investorsPeregrine VenturesIsrael Biotech Fund
Southeast Venture HoldingsFeb 2016SEC filingmedium confidence
AgTechSarasota, US
Kay D. Carter(Senior Vice President and Chief Financial Officer of Issuer)
Board seatRoss P. Barrett· per SEC Form D · $7M raise · filed Feb 2016
Starget PharmaOct 2024
BiotechShreveport, US
Sigal Kalmanson Cusnir(Executive Officer)
BoardRonen Kalmanson(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.